What management is recommended for an asymptomatic patient with Thyroid Imaging Reporting and Data System (TIRADS) category 2 adenomatous thyroid nodules and an isolated elevated free thyroxine (FT4) of 2.04 ng/dL (reference range 0.9–1.75 ng/dL)?

Measure TSH and obtain a radioactive iodine uptake scan to determine if this is a toxic adenoma causing subclinical hyperthyroidism

For an asymptomatic patient with TIRADS 2 adenomatous nodules and isolated elevated FT4 (2.04 ng/dL), the priority is determining whether the nodule is functionally autonomous and causing thyroid hormone excess, which requires different management than a benign non-functioning nodule.

Initial Diagnostic Approach

The elevated FT4 with TIRADS 2 nodules creates a critical diagnostic question: is this a toxic (autonomous) adenoma or a benign nodule with incidental thyroid dysfunction from another cause?

Measure serum TSH immediately 1. If TSH is suppressed (low), this indicates the nodule is likely functioning autonomously and producing excess thyroid hormone. The pattern you describe—elevated FT4 in the setting of adenomatous nodules—is consistent with a toxic adenoma, even in asymptomatic patients 2.

Obtain a radioactive iodine uptake (RAIU) scan with thyroid scintigraphy 1. This distinguishes:

• Hot/warm nodules (increased uptake in the nodule with suppressed surrounding tissue) = toxic adenoma requiring treatment
• Cold nodules (decreased uptake) = non-functioning nodule, and the elevated FT4 has another explanation

The RAIU is specifically indicated when the clinical presentation is not clearly diagnostic, and your scenario—adenomatous nodules with biochemical hyperthyroidism but no symptoms—fits this indication precisely 1.

Management Based on Findings

If Toxic Adenoma is Confirmed (Hot Nodule on Scan):

Definitive treatment with radioactive iodine (RAI) therapy or thyroidectomy is recommended 1. Even though the patient is currently asymptomatic, toxic adenomas with elevated FT4 warrant treatment because:

• Subclinical hyperthyroidism (suppressed TSH with normal/mildly elevated thyroid hormones) progresses to overt hyperthyroidism
• Cardiovascular complications (atrial fibrillation, heart failure) and bone loss occur even in subclinical disease
• The elevated FT4 of 2.04 ng/dL (above normal range) indicates this is beyond "subclinical" and represents mild overt hyperthyroidism

Long-term low-dose methimazole is mentioned as an occasional alternative 1, but RAI or surgery are the preferred definitive options for toxic nodular disease.

If Non-Functioning Nodule (Cold on Scan):

TIRADS 2 nodules are benign by definition 3. These require no FNA and no specific follow-up for malignancy risk. The ACR TI-RADS white paper explicitly states that only nodules with higher suspicion scores (TR3-TR5) require surveillance or biopsy 3.

However, you must then investigate the alternative cause of elevated FT4:

• Consider Graves' disease (though less likely with nodular disease)
• Evaluate for thyroiditis (painless/silent thyroiditis) 1
• Assess for medication effects or assay interference

Critical Pitfalls to Avoid

Do not assume TIRADS 2 nodules cannot be functional. The TIRADS classification addresses malignancy risk, not functional status 3. A benign-appearing adenoma can still be autonomously functioning and causing hyperthyroidism 2, 4.

Do not delay evaluation because the patient is asymptomatic. Elevated FT4 above the normal range (2.04 vs. upper limit 1.75) represents biochemical hyperthyroidism that carries cardiovascular and skeletal risks even without overt symptoms 1.

Do not perform FNA based on TIRADS 2 classification alone. These nodules have minimal malignancy risk and do not meet criteria for biopsy 3. The recent evidence showing higher-than-expected malignancy in some toxic adenomas 4 applies to surgically selected cohorts and should not change the approach to TIRADS 2 nodules, which by definition lack suspicious ultrasound features.

Algorithmic Summary

1. Check TSH → If suppressed, proceed to step 2
2. RAIU scan → Determines if nodule is functioning
3. If hot nodule → Treat with RAI or surgery 1
4. If cold nodule → Investigate alternative causes of elevated FT4; no nodule-specific treatment needed for TIRADS 2 3

The FT4/FT3 ratio may provide additional information if both are measured—a higher ratio can indicate increased malignancy risk in toxic nodules 4—but this applies primarily to surgical decision-making rather than initial evaluation.